TY - JOUR
T1 - The WOVEN trial
T2 - Wingspan one-year vascular events and neurologic outcomes
AU - Alexander, Michael J.
AU - Zauner, Alois
AU - Gupta, Rishi
AU - Alshekhlee, Amer
AU - Fraser, Justin F.
AU - Toth, Gabor
AU - Given, Curtis
AU - Mackenzie, Larami
AU - Kott, Brian
AU - Hassan, Ameer E.
AU - Shownkeen, Harish
AU - Baxter, Blaise W.
AU - Callison, R. Charles
AU - Yu, Wengui
N1 - Publisher Copyright:
©
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Background Prior studies evaluating the Wingspan stent for treatment of symptomatic intracranial atherosclerotic disease have included patients with a spectrum of both on-label and off-label indications for the stent. The WEAVE trial assessed 152 patients stented with the Wingspan stent strictly by its current on-label indication and found a 2.6% periprocedural stroke and death rate. Objective This WOVEN study assesses the 1-year follow-up from this cohort. Methods Twelve of the original 24 sites enrolling patients in the WEAVE trial performed follow-up chart review and imaging analysis up to 1 year after stenting. Assessment of delayed stroke and death was made in 129 patients, as well as vascular imaging follow-up to assess for in-stent re-stenosis. Results In the 1-year follow-up period, seven patients had a stroke (six minor, one major). Subsequent to the periprocedural period, no deaths were recorded in the cohort. Including the four patients who had periprocedural events in the WEAVE study, there were 11 strokes or deaths of the 129 patients (8.5%) at the 1-year follow-up. Conclusions The WOVEN study provides the 1-year follow-up on a cohort of 129 patients who were stented according to the current on-label use. It provides a more homogeneous patient group for analysis than prior studies, and demonstrates a relatively low 8.5% 1-year stroke and death rate in stented patients.
AB - Background Prior studies evaluating the Wingspan stent for treatment of symptomatic intracranial atherosclerotic disease have included patients with a spectrum of both on-label and off-label indications for the stent. The WEAVE trial assessed 152 patients stented with the Wingspan stent strictly by its current on-label indication and found a 2.6% periprocedural stroke and death rate. Objective This WOVEN study assesses the 1-year follow-up from this cohort. Methods Twelve of the original 24 sites enrolling patients in the WEAVE trial performed follow-up chart review and imaging analysis up to 1 year after stenting. Assessment of delayed stroke and death was made in 129 patients, as well as vascular imaging follow-up to assess for in-stent re-stenosis. Results In the 1-year follow-up period, seven patients had a stroke (six minor, one major). Subsequent to the periprocedural period, no deaths were recorded in the cohort. Including the four patients who had periprocedural events in the WEAVE study, there were 11 strokes or deaths of the 129 patients (8.5%) at the 1-year follow-up. Conclusions The WOVEN study provides the 1-year follow-up on a cohort of 129 patients who were stented according to the current on-label use. It provides a more homogeneous patient group for analysis than prior studies, and demonstrates a relatively low 8.5% 1-year stroke and death rate in stented patients.
KW - atherosclerosis
KW - intervention
KW - stenosis
KW - stent
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85102726354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102726354&partnerID=8YFLogxK
U2 - 10.1136/neurintsurg-2020-016208
DO - 10.1136/neurintsurg-2020-016208
M3 - Article
C2 - 32561658
AN - SCOPUS:85102726354
SN - 1759-8478
VL - 13
SP - 307
EP - 310
JO - Journal of NeuroInterventional Surgery
JF - Journal of NeuroInterventional Surgery
IS - 4
ER -